首页> 外文期刊>Behavioural neurology >Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?
【24h】

Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?

机译:帕金森病患者的多巴胺失调综合症不能令人满意地从立即释放的普拉克索转换为延长释放的普拉克索:激励机制的进一步线索?

获取原文
       

摘要

A small proportion of patients with Parkinson’s disease (PD), chronically under dopamine replacement therapy, may undergo an addiction-like behavioral disturbance, named dopamine dysregulation syndrome (DDS). This behavioral disorder is characterized by the increase of doses beyond those required for motor control, and its management remains difficu thus, early recognition and careful monitoring of at-risk individuals are crucial. We report the cases of two PD patients with a previous unsatisfactory switching from an immediate release (IR) to an extended release (ER) pramipexole formulation who developed DDS. PD patients unsatisfactorily switched from an IR to an ER formulation of dopamine agonists should be considered as at-risk individuals for DDS development.
机译:长期接受多巴胺替代疗法治疗的帕金森氏病(PD)的一小部分患者可能会出现成瘾样的行为障碍,称为多巴胺失调综合症(DDS)。这种行为障碍的特征是剂量增加,超出了运动控制所需的剂量,并且其管理仍然很困难。因此,早期识别和对危险个体进行仔细监控至关重要。我们报道了两名PD患者,他们先前从立即释放(IR)到延长释放(ER)普拉克索制剂的不满意转变而发展为DDS。 PD患者不能令人满意地从多巴胺激动剂的IR转换为ER制剂,应视为DDS发展的高危人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号